Last reviewed · How we verify
Metastatic renal cell carcinoma
Approved treatments
- Avastin · Washington University School of Medicine
- Cometriq · Exelixis
Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis. - Bevacizumab · Roche
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR. - Pembrolizuma · Memorial Sloan Kettering Cancer Center
- Cometriq · Exelixis Inc
Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis. - Avastin · Roche
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors. - Proleukin · Chiron
- Opdivo · Bristol-Myers Squibb
Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells. - Proleukin · University of Minnesota
Clinical guidelines
- FDA label — any
ZIRABEV, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC). - FDA label — any
MVASI, in combination with interferon-alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic renal cell carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic renal cell carcinoma treatment landscape brief
- Metastatic renal cell carcinoma treatment updates RSS
Frequently asked questions about Metastatic renal cell carcinoma
What drugs treat Metastatic renal cell carcinoma?
Tracked treatments include Avastin, Cometriq, Bevacizumab, Pembrolizuma, Proleukin, Opdivo.
What is the treatment for Metastatic renal cell carcinoma?
Standard treatment for Metastatic renal cell carcinoma includes Avastin, Cometriq, Bevacizumab, Pembrolizuma, Proleukin. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Metastatic renal cell carcinoma?
FDA label publishes guidelines for Metastatic renal cell carcinoma. 2 guideline references tracked.
Related
- Treatment landscape: Metastatic renal cell carcinoma patent cliff · Metastatic renal cell carcinoma CI report
- Treatment: Avastin · Washington University School of Medicine
- Treatment: Cometriq · Exelixis
- Treatment: Bevacizumab · Roche
- Treatment: Pembrolizuma · Memorial Sloan Kettering Cancer Center
- Treatment: Cometriq · Exelixis Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing